Fujian Aonong Biological Technology Group Incorporation Limited Class A

Fujian Aonong Biological Technology Group Incorporation Limited Class A

SSSE:603363
2.63
CNY
-0.09
(-3.31%)
-0.37EPS
7.67BMarket Cap
Apr 26Next Earn

Total Valuation

CNY

As of September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A carries a market capitalization of 7.67B, placing it among publicly traded companies globally. Its enterprise value stands at 9.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.67B
Enterprise Value9.86B

Important Dates

Fujian Aonong Biological Technology Group Incorporation Limited Class A's next confirmed earnings release is scheduled for April 26, 2027.

Earnings Date4/26/2027

Share Statistics

As of September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A has 2.73B shares outstanding.

Shares Outstanding2.73B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at 2.78.

PS Ratio0.72
PB Ratio2.78
P/TBV Ratio3.62

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.86B versus a market cap of 7.67B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.08

Financial Position

As of September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.39, indicating elevated leverage, while an interest coverage ratio of -5.44 demonstrates limited ability to service its debt obligations.

Current Ratio0.86
Quick Ratio0.12
Debt / Equity76.39
Debt / EBITDA-3.05
Interest Coverage-5.44

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A posted a negative return on equity (ROE) of -24.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.09, reflecting losses generated across the asset base. The company generates approximately 1.79M in revenue per employee across its workforce of 5,126.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.56 indicates how many times Fujian Aonong Biological Technology Group Incorporation Limited Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-24.51
Return on Assets (ROA)-8.09
Revenue Per Employee1.79M
Employee Count5,126.00
Inventory Turnover8.56

Taxes

CNY

Over the twelve months ended September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A recorded 55.97M in income tax expense. The company reported a pretax loss of -807.91M and -728.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax55.97M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A's stock has declined approximately 50.66% over the past 52 weeks. The 50-day moving average sits at 2.83, while the 200-day moving average is 3.31.

52-Week Price Change-50.66%
50-Day Moving Average2.83
200-Day Moving Average3.31

Income Statement

CNY

Over the twelve months ended September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A generated 9.16B in revenue and converted that into -728.07M in net income, yielding earnings per share of -0.37. EBITDA reached -771.98M, while operating income came in at -500.25M.

Revenue9.16B
Gross Profit153.25M
Operating Income-500.25M
Pretax Income-807.91M
Net Income-728.07M
EBITDA-771.98M
EBIT-771.98M
Earnings Per Share (EPS)-0.37

Balance Sheet

CNY

As of September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A holds 492.47M in cash and equivalents against 2.36B in total debt, resulting in a net debt position of 1.01B. Total book value stands at 2.76B, with working capital of -604.25M providing operational flexibility.

Cash & Cash Equivalents492.47M
Total Debt2.36B
Net Debt1.01B
Equity (Book Value)2.76B
Book Value Per Share1.01
Working Capital-604.25M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-134.94M

Margins

Over the twelve months ended September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A posted a gross margin of 1.67, reflecting its pricing power and cost economics. The operating margin of -5.46 and net profit margin of -7.95 provide insight into operational efficiency.

Gross Margin1.67
Operating Margin-5.46
Pretax Margin-8.82
Profit Margin-7.95
EBITDA Margin-8.43

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A paid dividends of 0.03 per share. The dividend payout ratio of -6.63 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fujian Aonong Biological Technology Group Incorporation Limited Class A shareholders.

Dividend Per Share0.03
Payout Ratio-6.63
Shareholder Yield1.21

Stock Splits

Fujian Aonong Biological Technology Group Incorporation Limited Class A's most recent stock split took place on October 21, 2020 with a 10:13 split ratio.

Last Split Date10/21/2020
Split Ratio10:13

Scores

As of September 30, 2026, Fujian Aonong Biological Technology Group Incorporation Limited Class A has an Altman Z-Score of 0.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.71